Thiogenesis Therapeutics Corp
TSXV:TTIView on OTC Pink - Current Information

  • LAST PRICE
    0.6000
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    0.5900/ 13
  • Ask / Lots
    0.6000/ 20
  • Open / Previous Close
    0.5900 / 0.6000
  • Day Range
    0.5900
    0.6000
  • 52 Week Range
    0.5900
    1.0600
  • Volume
    30,500

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 4, 2024

      Show headlines and story abstract

    • 9:02AM ET on Monday Nov 04, 2024 by Dow Jones
      Companies Mentioned: TTI

      San Diego, California--(Newsfile Corp. - November 4, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing novel thiol compounds, including precursors to cysteamine that have potent antioxidant and anti-inflammatory properties for mitochondrial diseases and related metabolic conditions; is pleased to announce that one of its core patents titled, "Methods For The Treatment of Cysteamine Sensitive Disorders," has been allowed by the European Patent Office (European Patent No. 18858763.8). The patent is scheduled to expire in September 2037. The new patent allowance in Europe is in addition to patents granted in this same patent family in United States in November 2021 and in Japan in 2023.

    • 9:01AM ET on Monday Nov 04, 2024 by Newsfile
      Companies Mentioned: TTIPF

      San Diego, California--(Newsfile Corp. - November 4, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing novel thiol compounds, including precursors to cysteamine that have potent antioxidant and anti-inflammatory properties for mitochondrial diseases and related metabolic conditions; is pleased to announce that one of its core patents titled, "Methods For The Treatment of Cysteamine Sensitive Disorders," has been allowed by the European Patent Office (European Patent No. 18858763.8). The patent is scheduled to expire in September 2037. The new patent allowance in Europe is in addition to patents granted in this same patent family in United States in November 2021 and in Japan in 2023.

Peers Headlines